Business
INVO Bioscience Expands Distribution of INVOcell Into the Pakistan Infertility Market with Galaxy Pharma Ltd.
- Signs distribution agreement with Galaxy Pharma Ltd., the clear market leader of infertility products and services in Pakistan - Seeks to expand access to
About this update from Invo Fertility, Inc.
[{"type":"text","content":"- Signs distribution agreement with Galaxy Pharma Ltd., the clear market leader of infertility products and services in Pakistan\n - Seeks to expand access to infertility care in the fifth most populous country in the world, Pakistan, with approximately 212 million people\n\n\nSARASOTA, Fla., Jan. 15, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced it has entered an exclusive distribution agreement with Galaxy Pharma Ltd. to distribute the INVOcell system within Pakistan. Galaxy Pharma is a leader in providing products and services to the country's current full-service In Vitro Fertilization (IVF) facilities, and has joint ventures operating an additional 21 facilities focused on administering Intrauterine Insemination (IUI) via OBGYN's. \n\n \n \n \n \n \n \n\n \n\"Pakistan represents a rapidly growing opportunity for INVOcell,\" commented Steve Shum, CEO of INVO Bioscience. \"The demand for infertility treatment in the country far surpasses the current capacity to service these patients through the available resources and capacity of IVF. The opportunity to offer the simplicity and effectiveness of the INVOcell solution, an efficient treatment technology with reduced infrastructure requirements, through existing IUI facilities provides a pathway to expand the overall addressable market. Partnering with Galaxy Pharma, the clear market leader in Pakistan, provides us with an ideal opportunity to meet the needs of the millions of potential patients that currently go untreated. We have already begun the necessary product registration process and upon completion will immediately begin working closely with Galaxy and their team to begin clinic introductions, training, sales and product delivery in the country. \"\nWith a population of approximately 212 million people, Pakistan is the fifth most populous country in the world. Currently, only 6,000 IVF cycles are conducted annually through 25 IVF centers which are located across just five out of the 25 major cities within the country. \n\"Galaxy Pharma was an early pioneer in the emerging fertility industry within Pakistan and has not only established itself a...